RyboDyn

Unlocking the dark proteome for high-resolution immunotherapies

RyboDyn is a business in therapeutics based in United States, founded in 2022.

Profile

RyboDyn, Inc. is targeting the dark proteome to make new immunotherapies. We are unlocking and validating previously undiscovered, disease-specific targets that will impact the treatment of cancer and autoimmune diseases by driving a new wave of targeted therapeutics. Our “targets-to-assets” therapeutics development program is supported by a scalable, in-house platform for lead discovery and optimization. We aim to deliver first-in-class assets that recognize these targets for treating solid tumors and diseases lacking effective treatment options.

Its activity falls under therapeutics; the profile below is assembled from public directory data.

Its base of operations is United States.

It is recorded at the SOSV portfolio company stage.

Recorded headcount: 2-10 employees.

Website: www.rybodyn.com